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background: Reduced myocardial external efficiency (MEE) might underlie the development of hypertrophic cardiomyopathy (HCM). However, 
direct evidence of inefficient ATP utilization at sarcomere level in human HCM is lacking. To reveal if sarcomere gene mutations underlie reduced 
MEE in HCM, energetic cost of contraction was studied in vitro in cardiac tissue from manifest HCM patients with MYH7 (MYH7mut) and MYBPC3 
(MYBPC3mut) mutations and in vivo in pre-hypertrophic mutation carriers.
Methods: Tension cost (ATP utilization/force) of sarcomere contraction was determined by measurements of force development and ATP utilization 
in myocardial preparations from 26 manifest HCM patients (11 MYBPC3mut, 9 MYH7mut, 6 sarcomere mutation-negative, HCMsmn). In addition, 
non-invasive quantification of MEE was performed, i.e. the ratio between external work and myocardial oxygen consumption (MVO2) in 28 pre-
hypertrophic mutation carriers (14 MYBPC3mut, 14 MYH7mut) and 14 healthy controls using in vivo [11C]-acetate PET and CMR imaging.
results: Higher tension cost was found in both MYBPC3mut and MYH7mut compared to HCMsmn samples at saturating [Ca2+]. Moreover, tension 
cost was significantly higher in MYH7mut than in MYBPC3mut (2.7±1.3 and 2.1±0.7, respectively, p=0.01). External work was significantly lower in 
both mutation carrier groups compared to controls, while MVO2 did not differ. As a result, MEE was significantly lower in both mutation carrier groups 
compared to controls (p<0.001). In addition, MEE of MYH7mut was significantly lower than in MYBPC3mut (30±4 and 37±7%, respectively, p=0.01).
conclusion: This study provides direct evidence that sarcomere mutations perturb energetic cost of cardiac contraction. Gene-specific severity 
of cardiac abnormalities may underlie differences in disease onset and suggests that early initiation of metabolic treatment may be beneficial in 
particular in MYH7 mutation carriers.
